- Syntec Optics (OPTX, Financial) enables non-incisional optics for presbyopia treatment.
- The U.S. presbyopia market affects approximately 128 million people.
- The global market for myopia and presbyopia treatment is valued at $20.3 billion in 2025.
Syntec Optics Holdings, Inc. (Nasdaq: OPTX), a leader in optics manufacturing, has announced its active involvement in the clinical development of non-incisional vision correction technology specifically targeting presbyopia. This marks a strategic entry into the rapidly growing global myopia and presbyopia treatment market, projected to be valued at $20.3 billion by 2025. This initiative aims to provide safer and more convenient alternatives to traditional surgical methods.
Presbyopia, an age-related condition affecting approximately 128 million individuals in the United States, results in the gradual loss of the ability to focus on nearby objects. Syntec Optics is leveraging its advanced optical manufacturing capabilities to support the development of innovative solutions that offer less invasive, quicker recovery options compared to traditional corrective lenses or surgical interventions.
Syntec Optics' involvement in this emerging segment underscores its commitment to improving healthcare through precision optics manufacturing. By focusing on non-incisional optical solutions, the company aims to cater to a significant unmet need in the vision care market, potentially enhancing the quality of life for millions experiencing age-related vision loss.
